Finanzen von Opus Genetics Inc (IRD)IRDOpus Genetics Inc

Evaluating the bottom line, Opus Genetics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2182.78%, while the net margin is -1072.58%. These profitability ratios, combined with a Return on Equity (ROE) of -4796.52%, provide a clear picture of how effectively IRD converts its operational activities into shareholder value.

In the context of the broader market, IRD competes directly with industry leaders such as ENTA and TTRX. With a market capitalization of $341.10M, it holds a leading position in the sector. When comparing efficiency, IRD's gross margin of 100.00% stands against ENTA's 100.00% and TTRX's N/A. Such benchmarking helps identify whether Opus Genetics Inc is trading at a premium or discount relative to its financial performance.

Opus Genetics has shown fluctuating revenue, with Q1 2026 revenue at $2.157 million and a gross margin consistently at 100%. However, net income remains negative, with a significant loss of -65.5 million in Q1 2026. The current ratio is strong at 12.19, indicating good short-term financial health.